Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sindilizumab plus palbociclib for first-line advanced or unresectable liposarcoma
ChiCTR2400087517Phase 2Not yet recruiting
- Sponsor
- Guangdong Provincial Hospital of Traditional Chinese Medicine
- Start
- Jul 2024
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sindilizumab and palbociclib in Liposarcoma, sponsored by Guangdong Provincial Hospital of Traditional Chinese Medicine. Primary endpoint: Progression-free survival. Planned start Jul 2024; status: not yet recruiting.
02
Drugs
sindilizumabpalbociclib
03
Conditions
Liposarcoma
Beyond the preview
Go deeper on ChiCTR2400087517.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400087517.